Pharmacodynamic and Antitumor Activity of BI 836880, a Dual VEGF and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition

Data Supplement

• Supplemental Data -

  Supplementary Table S1. Mutational status, histology and origin of patient-derived xenograft models.

  Supplementary Table S2. Summary of BI 836880 binding characteristics.
  

  Supplementary Table S3. Least squares means (predicted) and treatment ratio for tumor volume (mm3): results from a repeated measurement mixed model comparing treatment with anti-PD-1 plus anti-VEGFR2 with anti-PD-1 plus anti-VEGFR2 plus anti-ANG2.
  

  Supplementary Figure 1.